Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator (CRT-D), CRT-Pacemaker (CRT-P)), By Application (Heart Failure Management, Arrhythmia Management, Others), By End User (Hospitals, Cardiac Clinics, Ambulatory Surgical Centers (ASCs)) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Cardiac Resynchronization Therapy (CRT) Market Size

The global cardiac resynchronization therapy (CRT) market size was valued at USD 4.55 billion in 2023 and is projected to reach USD 7.19 billion by 2032 growing at a CAGR of 4.80% during the forecast period (2024-2032).

Cardiac resynchronization therapy, also known as biventricular pacing, is a method that helps patients with arrhythmias normalize their heartbeat and other disease-related disorders. A pacemaker is frequently implanted below the collarbone during this procedure. Cardiac resynchronization therapy defibrillators and cardiac resynchronization treatment pacemakers are two types of therapy that are commonly used. It is especially beneficial for people with heart failure whose left and right heart lobes do not contract together. Rapid technological advancements are one of the key trends escalating market growth. The adoption of a sedentary lifestyle, the growing geriatric population, and the increasing prevalence of cardiovascular diseases are also stimulating the market's development. 

Cardiac Resynchronization Therapy Market Growth Factors

Increasing Prevalence of Cardiovascular Diseases

Despite developments in prevention & treatment, sudden cardiac death remains a leading cause of mortality and is accountable for nearly half of all deaths from cardiovascular ailments. The increasing prevalence of cardiac disorders and associated risk factors are expected to increase the demand for cardiac resynchronization therapy devices. Heart failure is among the significant reasons for death around the globe. 

• According to CDC, as of September 2020, around 6.2 million adults in the U.S. suffer from cardiac conditions. Furthermore, as per the American College of Cardiology Foundation, prevalent cases of cardiovascular diseases nearly doubled from 1990 to 2019. Hence, the increasing prevalence of cardiovascular diseases is anticipated to boost the demand for various treatment options, including cardiac resynchronization therapy devices.

Rising Sedentary Lifestyle 

Physical inactivity is a primary public concern as it is linked to the second-largest number of deaths, after tobacco consumption, in the U.S. Physical inactivity can lead to morbid obesity and many other chronic diseases, such as cardiac disorders and diabetes. Extended periods of inactivity in otherwise physically active individuals have been commonly observed to increase symptoms of CVD in diabetic and atherosclerotic patients. Major consequences of this lifestyle are cardiac disorders, such as stroke, myocardial infarction, and angina.

• According to CDC, as of 2019, about 1 in 4 U.S. individuals sit for over 8 hours a day, 44% do no moderate to vigorous physical activity in a week, and only 4% spend less than 4 hours a day sitting and being active as well. It is anticipated to increase the demand for CRT devices. A sedentary lifestyle can lead to obesity and hypertension, the critical risk factors for CVDs. Obesity continues to be one of the essential public health issues. According to a study published online in Pediatrics, obesity rates among children jumped significantly during the first months of the COVID-19 pandemic. Across the board, there has been a 2% increase in obesity in a year.

Hence, a growing sedentary lifestyle is also estimated to drive the market.

Market Restraining Factors

Product Recall

• In February 2021, Medtronic initiated the recall of Viva, Evera, Brava, Amplia, Claria, Visia, and Compia, Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT-Ds), which were distributed between 31 August 2012 and 9 May 2018. The reason for the recall was an unexpected and rapid decrease in battery life.
• In June 2021, Boston Scientific Corporation initiated the recall of the INGENIO family of pacemakers and CRT-Ps. These include ADVANTIO DR EL, INGENIO DR EL, and VITALIO DR EL. The devices recalled were manufactured between September 2011 and December 2018 and distributed between 1 November 2011 and 1 August 2020. Around Forty-eight thousand devices were recalled in the U.S. The reason for the recall was the risk of the device transitioning to safety mode.
• In February 2018, Medtronic recalled certain ICDs and CRT-Ds due to a manufacturing defect. This defect caused an out-of-specification gas mixture inside the device. Hence, it would prevent the device from delivering the electrical shock required to pace a patient's heartbeat or revive the patient in case of a cardiac arrest. This recall affected devices with product codes LWS and NIK that were manufactured between 13 July 2013 and 8 August 2017. Around 48 units in the U.S. were recalled during this process. Hence, an increasing number of product recalls is expected to impact the adoption negatively of cardiac resynchronization therapy devices, restricting the market over the projected period.

Market Opportunities

Technological Advancements

CRTs have been upgraded with numerous new features, such as longer battery life and smaller size. As a result, vendors have been focusing more on the development of innovative CRTs. For instance, in January 2018, MicroPort Scientific Corporation launched Smart Touch, a new tablet-based programmer in Europe. The product is used with cardiac resynchronization devices, pacemakers, and defibrillators. 

• In March 2017, Biotronik released a new lineup of Cardiac Resynchronization Therapy (CRT) devices, called the Silvia series, thus extending the company's product offerings. Furthermore, technical developments and digitization in healthcare technologies, as well as an increase in developing markets with an expanding older population profile, will generate new opportunities for the cardiac resynchronization treatment demand during the anticipated period of 2022-2030.

Regional Insights

The North America market is anticipated to maintain its dominance during the forecast period due to its increasing geriatric population and growing regulatory approvals. The North America cardiac resynchronization therapy (CRT) market was valued at USD 2,311 Million in 2021. It is expected to reach an expected value of USD 4,167 Million by 2030 at a CAGR of 7% during the forecast period. The growth can be attributed to various factors such as increasing awareness about the benefits of cardiovascular devices, high disposable income, and the presence of advanced healthcare infrastructure. 

In addition, several medical device vendors present in this region are involved in providing cardiovascular care globally. These companies are focused on launching new and advanced products, including features such as miniaturization & increased battery life, which is anticipated to further drive market growth.

The Asia-Pacific market is projected to grow at the fastest CAGR over the next few years. The Asia-Pacific cardiac resynchronization therapy (CRT) market was valued at USD 1,231 Million in 2021. It is expected to reach an expected value of USD 2,487 Million in 2030 at a CAGR of 8% during the forecast period. This is due to rising medical infrastructure, an older population, positive financial situations, strategic actions by significant firms, and an increased incidence of heart disorders.

Developed markets, such as Japan and Australia, are also rapidly adopting new technological advancements in these devices. For instance, remote monitoring in cardiac implantable devices was found to be adopted rapidly across Asia-Pacific, especially in CRT/CRTDs, despite having greater costs. In New Zealand, data on cardiac implantable electronic devices was studied between 2014 and 2017. 155 patients received CRT-D implants, while 175 received CRT-P implants during the period. Patients who received a new CRT-P were found to be more likely to be female and older, compared to new primary prevention CRT-D implants.

Cardiac Resynchronization Therapy (CRT) Market Segmentation Analysis

By Product

In the market, CRT-Defibrillators (CRT-D) dominate due to their advanced capabilities in both resynchronization and defibrillation, which are essential for managing severe heart failure and ventricular arrhythmias. Among CRT-Ds, Biventricular CRT-Ds are the leading segment, offering superior resynchronization of all three heart chambers, improving cardiac function and patient outcomes. CRT-Pacemakers (CRT-P), while important, are typically used in less severe cases or as a supplemental therapy, thus holding a smaller market share compared to CRT-Ds. The preference for CRT-Ds stems from their comprehensive therapeutic benefits and advanced technology.

By Application

In the market, Heart Failure Management dominates due to the high prevalence of chronic heart failure and the significant benefits CRT provides in improving heart function and patient survival. CRT is particularly effective in synchronizing cardiac contractions, which is crucial for heart failure patients. This application drives the largest market share, as CRT devices offer substantial improvements in symptoms and quality of life. Although Arrhythmia Management is also important, it addresses a narrower range of conditions, making heart failure management the primary focus and leading segment in the CRT market.

By End User

In the market, Hospitals dominate as the primary end-user due to their comprehensive infrastructure and resources required for complex CRT procedures. Hospitals are equipped with specialized cardiac teams, advanced diagnostic tools, and surgical facilities, making them the preferred setting for implanting CRT devices. The demand for CRT in hospitals is driven by their capacity to handle severe and complex cases of heart failure and arrhythmias.

Recent Developments

1. July 2023, Biotronik SE & Co. KG has received U.S. Food and Drug Administration (FDA) approval for its next-generation Amvia Edge pacemakers and cardiac resynchronization therapy (CRT) devices.